Background: Systematic reviews comparing untargeted antifungal treatment with placebo or no treatment in critically ill patients have provided conflicting results. We aimed to assess patientimportant benefits and harms of untargeted antifungal therapy vs. placebo or no treatment in adult patients with complicated intraabdominal infection. Methods: We conducted a systematic review with meta-analysis and trial sequential analysis of randomised clinical trials assessing untargeted antifungal therapy compared to placebo or no treatment in adults with complicated intra-abdominal infection. We used the Cochrane and GRADE methodologies and exclusively assessed patient-important outcomes. Two independent authors screened trials for eligibility, extracted data and assessed risk of bias. We performed conventional meta-analyses, including sensitivity and subgroup analyses, and trial sequential analysis to assess the risk of random errors and to estimate trial sequential analysis adjusted confidence intervals. Results: We included six trials (1,067 patients) in the review, and four trials reported data on the predefined outcome measures and were included in the meta-analysis. Three of the four trials had high risk of bias. We observed no statistically significant difference in mortality (relative risk 0.58, 95% confidence interval 0.24-1.39) or in any of the other patient-important outcomes between untargeted antifungal treatment and placebo or no treatment (low/very low quality of evidence). Trial sequential analysis demonstrated lack of data and high risk of random errors.
Intra-abdominal infections are the second most frequent cause of sepsis in the intensive care unit (ICU) patients. 1 Complicated intra-abdominal infection or peritonitis is characterised by inflammation of the peritoneum, most often caused by bacteria and/or fungi. The condition is associated with high morbidity and mortality despite administration of relevant antibiotics and/or surgical interventions. [1] [2] [3] In a recent retrospective cohort of critically ill patients with sepsis due to peritonitis, fungal specimens were found in 52% of all patients. 4 Patients with fungal infection had a significantly higher rate of refractory peritonitis and a higher overall mortality compared to patients without fungal infection. 4 Untargeted antifungal treatment is defined as any antifungal intervention initiated before definitive microbiological evidence of fungal infection exists. [5] [6] [7] [8] At present, three different untargeted treatment strategies have been defined, namely prophylaxis, pre-emptive and empirical therapy. [5] [6] [7] [8] Antifungal prophylaxis is used in patients with high risk of developing invasive fungal infections, including critical illness, recent abdominal surgery, haematologic malignancy, organ transplantation and treatment with glucocorticoids or broad-spectrum antibiotics, and risk stratification has been suggested. [5] [6] [7] [8] [9] [10] Pre-emptive antifungal treatment is administered in response to direct or indirect microbiological evidence of fungi without clinical suspicion of invasive fungal infection. [5] [6] [7] [8] Finally, empirical antifungal treatment is used in patients with known risk factors and suspicion of fungal infection. [5] [6] [7] [8] In daily clinical practice, it is often difficult to distinguish the different untargeted antifungal treatment strategies.
Two previous systematic reviews assessed prophylactic antifungal treatment with fluconazole or ketoconazole in non-neutropenic critically ill patients. Both demonstrated a reduction in invasive fungal infection and all-cause mortality in patients receiving antifungal treatment compared to placebo or no treatment. 11, 12 However, in a recently updated Cochrane review including a total of 2,761 non-neutropenic, critically ill adults and children, untargeted antifungal treatment did not significantly reduce mortality (moderate quality of evidence). 5 The data indicated a reduction in rates of invasive fungal infections, but the quality of evidence was low. 5 Existing systematic reviews and meta-analysis on untargeted antifungal treatment are confined to critically ill patients in general. Whether certain subgroups of critically ill patients, including patients with complicated intra-abdominal infection, benefit from treatment with untargeted antifungal therapy is unknown. Consequently, we aimed to assess patient-important benefits and harms of untargeted antifungal therapy vs. placebo or no treatment in randomised clinical trials (RCTs) of adult patients with complicated intra-abdominal infection. We hypothesised that untargeted antifungal treatment is beneficial in patients with complicated intra-abdominal infection.
Methods
This systematic review has been conducted in accordance with the methodologies of the Cochrane Collaboration, Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) statement, and the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. [13] [14] [15] A protocol including a statistical analysis plan has been published, 16 and the review was registered in the International Prospective Register of Systematic Reviews (PROSPERO) before the literature search was done (registration number CRD42016053508).
Research question
Is untargeted antifungal treatment superior to placebo or no treatment in adult patients with complicated intra-abdominal infection?
Eligibility criteria
We included RCTs assessing any untargeted antifungal therapy in adult patients with complicated intra-abdominal infection (as defined in the original trials) regardless of publication status, publication period, blinding and language. Trials were included regardless of the immune status of the patients. The intervention of interest was untargeted antifungal therapy, including azoles, echinocandins, polyenes, allylamines and nucleoside analogues in any dose, timing, formulation and duration. The comparators were placebo or no treatment. Trials were permitted to have more than one intervention group.
We excluded (1) crossover trials, (2) quasirandomised trials, (3) RCTs conducted in animals, children or healthy subjects and (4) trials not reporting patient-important outcomes. 16 
Search strategy
We systematically searched the Cochrane Library (Issue 1, January 2017), MEDLINE (1946 onwards), EMBASE (1980 onwards) and Epistemonikos. The latest search was performed on 9 July 2017. In addition, we handsearched reference lists of relevant trial papers and other systematic reviews. Unpublished trials were sought identified by performing an equivalent search strategy in other registries (e.g. clinicaltrials.gov, European Clinical Trials Database, etc.). The search strategy is presented in the electronic supplementary material (Appendix S1).
Trial selection
Two independent authors (MWP and FR) screened titles and abstracts of the identified trials. Relevant trials were evaluated in full text for eligibility. Disagreements were resolved by discussion between authors and finally by consensus among all authors.
Data extraction
Two authors independently extracted data in duplicate using a standardised data extraction form (MWP and FR). Trial authors were contacted for additional data if relevant data were missing. However, the authors provided no data upon request (one trial). 17 Data items extracted included trial characteristics, patient characteristics, details of intervention(s) and comparator (s), risk of bias and the predefined outcome measures. We included data from intention-totreat analysis if possible. Disagreements were resolved by the discussion between data extracting authors and finally by consensus among all authors.
Risk of bias assessment
Two authors (MWP and FR) independently assessed the risk of bias of the included trials in accordance with the recommendations by the Cochrane Collaboration. 15 The domains assessed included (1) random sequence generation, (2) allocation concealment, (3) blinding of participants and personnel, (4) blinding of outcome assessors, (5) incomplete outcome data, (6) selective outcome reporting and (7) other bias, including baseline imbalance, early stopping and bias due to vested financial interest or academic bias. If one or more domains were judged as being high or unclear, we classified the trial as having overall high risk of bias.
GRADE
The quality of evidence for each outcome was assessed according to GRADE (Table 3) . 13 The quality of evidence was downgraded for risk of bias, inconsistency, indirectness, imprecision and publication bias. 13 Consequently, the quality of evidence was classified as high, moderate, low or very low.
Outcome measures
We exclusively assessed patient-important outcome measures. 18 The primary outcome measure was all-cause short-term mortality (≤ 90 days, including in-ICU and in-hospital mortality). Secondary outcomes included (1) long-term mortality (> 90 days), (2) adverse events (as defined in the original trials) at longest followup, (3) duration of mechanical ventilation, (4) days free of mechanical ventilation, (5) need for renal replacement therapy at longest follow-up, (6) days free of renal replacement therapy, (7) duration of vasopressor/inotropic support, (8) days free of vasopressors/inotropes, (9) emergence of antibiotic resistance at longest followup, (10) emergence of fungi not susceptible to given antifungal agent, (11) ICU length of stay (LOS), (12) hospital LOS and (13) and quality of life (as defined in the original trials) at longest follow-up. 16 If an outcome was reported at multiple time points, we assessed that with longest follow-up.
Statistical methods
We used Review Manager (RevMan 5.3) for the conventional meta-analyses and the TSA program version 0.9 beta available from Copenhagen Trial Unit, Denmark (www.ctu.dk/TSA) for the trial sequential analyses (TSA).
We estimated summary relative risk (RR) with 95% confidence interval (CI) for dichotomous outcomes and mean difference (MD) with standard deviation (SD) for continuous outcomes. We used both fixed effect and random effects modelling and reported the most conservative estimate. To quantify statistical heterogeneity, we calculated inconsistency factor (I 2 ) and diversity factor (D 2 ). In the zero event trials, empirical continuity correction was applied. 19 We also aimed to assess the risk of small trial bias (publication bias) by funnel plots. However, this was not applicable as < 10 trials were included. 20 The risk of random errors was assessed by TSA, which is a sample size calculation (interim analysis) for meta-analyses that widens the CIs in case data are too sparse to draw firm conclusions. 21 We applied trial sequential monitoring boundaries according to an information size suggested by the trials with low risk of bias and an a priori 20% relative risk difference (reduction or increase), alpha 5%, beta 90% and a control event proportion as in the control arm. 21 
Subgroup analysis
We planned a number of subgroup analyses 16 but only the following five could be conducted: (1) trials with overall low risk of bias vs. trials with overall high risk of bias, (2) prophylactic vs. pre-emptive vs. empirical treatment strategies, (3) non-ICU trials vs. ICU trials, (4) trials published before the year 2000 vs. trials published in and after the year 2000 and (5) patients with vs. without septic shock. We used chi-square test to assess statistical heterogeneity between studies (test of interaction) with a P-value of 0.10 considered statistically significant.
Results
A total of 501 records were identified through the search and an additional 20 records by hand-searching reference lists of relevant trials (Fig. 1 ). Of these, 93 articles were screened in full text for eligibility, six trials comprising 1067 patients were included in the review and four trials were included in the metaanalysis. 17, [22] [23] [24] [25] [26] The reasons for exclusion were wrong study design, wrong patient population and wrong intervention (Fig. 1) . 
Characteristics of trials
Detailed information regarding trial characteristics is provided in Table 1 . Three trials were conducted in Europe; one single-centre and two multi-centre trials. 17, 22, 24 The remaining trials were performed in the Middle East, Asia and South America; all were single-centre trials. 23, 25, 26 Two trials included ICU patients (one surgical ICU patients and one mixed ICU patients), 17, 23 two included hospitalised surgical patients 22, 24 and two included outpatients on continuous ambulatory peritoneal dialysis (CAPD). 25, 26 The most commonly assessed intervention was fluconazole compared to placebo (four trials). 17, [22] [23] [24] The two remaining trials assessed micafungin and nystatin compared to no treatment in CAPD outpatients. 25, 26 The two trials on CAPD patients with peritonitis did not provide data on the predefined outcome measures. 25, 26 Consequently, four trials were included in the meta-analysis.
17,22-24

Risk of bias assessment
Detailed information regarding each bias domain is provided in Fig. 2 . We characterised all trials, except one, as having overall high risk of bias 23 with the main reasons being unclear allocation concealment 17, 25, 26 and risk of financial bias. 17, 22, 24 Outcome measures All-cause short-term mortality Four trials (n = 430) reported data on all-cause short-term mortality 17, [22] [23] [24] ; one of these had low risk of bias (Fig. 2) . 23 In conventional meta-analysis, we observed no statistically significant difference in short-term mortality between untargeted antifungal treatment and placebo/no treatment (random effect: RR 0.58, 95% CI: 0.24-1.39, I
2 : 52%, Fig. 3) . 17, [22] [23] [24] We could not perform TSA as only 3.1% of the required information size of 13,871 patients had been accrued.
The subgroup analysis comparing prophylactic vs. pre-emptive vs. empirical antifungal treatment suggested lower short-term mortality in patients receiving prophylactic antifungal treatment as compared to placebo/no treatment (test of interaction, P = 0.03) ( Table 2 ). The other predefined subgroup analyses indicated no differences between subgroups (Table 2) .
Adverse events
One trial with high risk of bias (n = 43) reported data on adverse events. 22 No difference between patients receiving antifungal treatment compared to placebo/no treatment was suggested (random effect: RR 0.61, 95% CI: 0.29-1.30). 22 We could not perform TSA as only 3.3% of the required information size of 1,303 patients had been accrued.
Duration of vasopressor/inotropic support
One trial with low risk of bias (n = 34) reported data on duration of vasopressor/inotropic support. 23 The results indicated a prolonged duration of shock in patients receiving antifungal treatment compared to placebo (random effect: MD 2.70, 95% CI: 1.77-3.63). 23 TSA highlighted high risk of random errors, as only~21% of the required information size of 161 patients had been accrued (TSA-adjusted MD: 2.70, 95% CI: 0.46-4.94).
ICU and hospital length of stay One trial with low risk of bias (n = 34) reported data on ICU LOS. 23 Results indicated a prolonged ICU LOS in patients receiving antifungal treatment compared to placebo (random effect: MD 7.10, 95% CI: 3.88-10.32). 23 TSA highlighted high risk of random errors as only~16% of the required information size of 215 patients had been accrued (TSA-adjusted MD 7.10, 95% CI: À1.97 to 16.17).
Another trial (n = 43, high risk of bias) reported median data on hospital LOS with no difference between the two groups. 22 
Additional outcomes
No trials reported data on long-term mortality, duration of mechanical ventilation, days free of mechanical ventilation, need for renal replacement therapy, days free of renal replacement therapy, days free of vasopressors/inotropes, emergence of antibiotic resistance, emergence of fungi not susceptible to given antifungal agent or quality of life. 
Discussion
In this systematic review of RCTs with metaanalysis and TSA, we found low/very low quantity and quality of evidence supporting untargeted antifungal therapy in adult patients with complicated intra-abdominal infection with no firm evidence for benefit or harm.
All-cause short-term mortality
The conventional meta-analysis showed a nonstatistically significant reduction in all-cause mortality with untargeted antifungal treatment. TSA could not be conducted due to the limited sample size with resulting high risk of random errors. No difference between patients with and without septic shock or ICU and non-ICU patients was suggested in the subgroup analyses ( Table 2 ). The subgroup analysis comparing prophylactic, pre-emptive and empirical antifungal treatment indicated a lower mortality in patients receiving prophylaxis, but the detected difference between the groups is at a high risk of a type 1 error due to the small sample size. The point estimate suggested a possible mortality reduction from untargeted antifungal treatment; however, the overall quality of evidence was very low (downgraded for risk of bias, inconsistency and imprecision) with no firm evidence for benefit or harm (Table 3) .
Adverse events
Only one trial reported data on adverse events. 22 The results suggested no difference between antifungal treatment and placebo/no treatment. However, the risk of random errors was high due to the small sample size. The overall quality of evidence was very low (downgraded for risk of bias and imprecision; Table 3 ). Consequently, no firm evidence for benefit or harm of untargeted antifungal treatment on adverse events is available. Importantly, adverse events related to antifungal treatment are likely underestimated.
Duration of vasopressor/inotropic support
A prolonged duration of vasopressors/inotropes in patients receiving antifungal treatment was Single-dose placebo perioperatively -All-cause short-term mortality GCS, Glasgow Coma Scale; h: hours; ICU, Intensive Care Unit; LOS, length of stay; mg, milligrams; n/a, not applicable.
Acta Anaesthesiologica Scandinavica 62 (2018) [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] indicated by the data of a single trial. However, TSA highlighted a high risk of random errors due to a very limited sample size. The overall quality of evidence was low (downgraded for imprecision) with no firm evidence for benefit or harm (Table 3) .
ICU length of stay
One trial indicated a prolonged ICU LOS in patients receiving antifungal treatment compared to placebo, but results were not confirmed by TSA. 23 Importantly, the sample size was very limited, and there was a high risk of random errors. The overall quality of evidence was low (downgraded for imprecision) with no firm evidence for benefit or harm (Table 3) .
Strengths and limitations of the review
We followed the recommendations of the Cochrane Collaboration, 15 PRISMA statement 14 and GRADE, 13 including a pre-experimentally published protocol, 16 an independent systematic literature search with no language restrictions, independent data extraction and risk of bias assessment, contact to authors for further details, and inclusion of trials irrespective of publication status. In addition, we assessed the risk of random errors (spurious findings due to repetitive testing) with the application of TSA to increase the robustness of the analyses. We did not include observational studies of antifungal treatment, 10, 27, 28 as they inherently increase the risk of inflated estimates. 29 We included data from RCTs only and focused exclusively on patient-important outcome measures, as non-patient-important outcome measures (surrogate outcomes) inherently overestimate the effects of interventions. 30 The results of our review come with some limitations. The included trials were somewhat heterogeneous in regard to setting, population and intervention, for example, two trials included CAPD patients with peritonitis, 25, 26 which is a different entity than patients undergoing major abdominal surgery 17, 22, 24 or ICU patients. 17, 23 However, these two trials were not included in the meta-analysis, as they did not provide data on any of our predefined outcome measures. Also, one of the subgroup analyses indicated a difference between prophylaxis and pre-emptive treatment, although the amount of data was very limited. The type and dosing of antifungal agents were not a predefined subgroup analysis. The remaining subgroup analyses did not indicate heterogeneity. Results from subgroup analyses should be interpreted carefully because of the high risk of systematic and random errors in the primary analysis. Five of six included trials were characterised as having an overall high risk of bias. This increases the risk of falsely inflated estimates. 29 In general, limited data on the predefined patient-important outcomes were available. This increases the risk of type 1 and 2 errors (imprecision). A priori, we choose a 20% relative risk difference as clinically relevant. 16 Consequently, we are not able to rule out treatment effects smaller than 20%.
Relation to other reviews and implication for future research
This review is the first systematic review of RCTs with meta-analysis and TSA comparing untargeted antifungal treatment with placebo or no treatment in adult patients with complicated intra-abdominal infection. The effects of antifungal prophylaxis have previously been assessed in non-neutropenic critically ill adult patients. 5, 11, 12 In two former systematic reviews, authors concluded that antifungal prophylaxis safely reduced mortality and invasive fungal infections without increasing the risk of resistant fungi. 11, 12 On the contrary, a recently updated Cochrane review demonstrated no difference in mortality (moderate quality of evidence), but a reduced risk of invasive fungal Summary estimates for untargeted antifungal treatment as compared to no treatment/placebo. n/a, not applicable. infections with antifungal treatment (low quality of evidence). 5 In accordance with these findings, our results indicate no difference in mortality or other patient-important outcomes between untargeted antifungal treatment and placebo or no treatment (low/very low quality of evidence) in adults with complicated intraabdominal infection.
Diagnosing fungal infection is challenging, as symptoms and signs are non-specific and mimic those of bacterial infection. 9 Also, the time to acquire definite diagnosis may take several days as it is still largely based on cultures. For these reasons, untargeted antifungal strategies may appear attractive. However, several potential disadvantages of antifungal treatment exist, including drug interactions, side effects, development of resistant fungi and economical expenses.
1 Thus, it is important to balance benefits and harms of antifungal treatment in various patient groups before using it as routine in daily clinical practice.
Conclusions
The quantity and quality of evidence supporting untargeted antifungal treatment in adult patients with complicated intra-abdominal infections is low to very low with no firm evidence for benefit or harm. High-quality RCTs balancing the benefits and harms of untargeted antifungal treatment in patients with intra-abdominal infection are needed to offer the best care to these patients at the lowest possible cost and to limit the development of resistant fungi. 
